Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period

Invasive lobular carcinoma (ILC) accounts for 5–15% of invasive breast cancers. Typical ILC is oestrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative. Atypical biomarker profiles (ER- and HER2+, ER+ and HER2+ or triple negative) appear to differ from typical IL...

Full description

Saved in:
Bibliographic Details
Published in:Breast (Edinburgh) 2024-08, Vol.76, p.103739, Article 103739
Main Authors: Quirke, N.P., Cullinane, C., Turk, M.A., Shafique, N., Evoy, D., Geraghty, J., McCartan, D., Quinn, C., Walshe, J.M., McDermott, E., Rutherford, C., Prichard, R.S.
Format: Article
Language:English
Subjects:
Breast
Cancer
Lobular
Neoadjuvant chemotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-712c0ee785b8b24806a4d651b5e493e9685c7742a61eb1b7482b25f61dfd645a3
cites cdi_FETCH-LOGICAL-c474t-712c0ee785b8b24806a4d651b5e493e9685c7742a61eb1b7482b25f61dfd645a3
container_end_page
container_issue
container_start_page 103739
container_title Breast (Edinburgh)
container_volume 76
creator Quirke, N.P.
Cullinane, C.
Turk, M.A.
Shafique, N.
Evoy, D.
Geraghty, J.
McCartan, D.
Quinn, C.
Walshe, J.M.
McDermott, E.
Rutherford, C.
Prichard, R.S.
description Invasive lobular carcinoma (ILC) accounts for 5–15% of invasive breast cancers. Typical ILC is oestrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative. Atypical biomarker profiles (ER- and HER2+, ER+ and HER2+ or triple negative) appear to differ from typical ILCs. This study compared subtypes of ILC in terms of clinical and pathological parameters, and response to neoadjuvant chemotherapy (NACT) according to biomarker profile. All patients with ILC treated in a single centre from January 2005 to December 2020 were identified from a prospectively maintained database. Clinicopathologic and outcome data was collected and analysed according to tumour biomarker profile. A total of 582 patients with ILC were treated. Typical ILC was observed in 89.2% (n = 519) and atypical in 10.8% (n = 63). Atypical ILCs were of a higher grade (35% grade 3 vs 9.6% grade 3, p 
doi_str_mv 10.1016/j.breast.2024.103739
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d4ce1749f6524f5b865c548323a5adc4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960977624000705</els_id><doaj_id>oai_doaj_org_article_d4ce1749f6524f5b865c548323a5adc4</doaj_id><sourcerecordid>3056668572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-712c0ee785b8b24806a4d651b5e493e9685c7742a61eb1b7482b25f61dfd645a3</originalsourceid><addsrcrecordid>eNp9kc2L1TAUxYsoznP0PxDJ0k2f-U6LIMjgx4MBN7oOt8ntvJS2qUnfg7edv9yMHWfpKnA59_xyz6mqt4zuGWX6w7DvEkJe95xyWUbCiPZZtWNK8FrQhj6vdrTVtG6N0VfVq5wHSmkrdPOyuhKNUZJJuqvuD_MZcjgjGWN3GiERB8mFOU5AYk_WI5IN85G4MczBxQXWYxzjXXBkSbEPIxKYPUmYlzhnJGskM0bww-kM80rcEadYbBIsFxLPmAgQpuoLFtSCKUT_unrRw5jxzeN7Xf36-uXnzff69se3w83n29pJI9faMO4oomlU13RcNlSD9FqxTqFsBba6Uc4YyUEz7FhnZMM7rnrNfO-1VCCuq8Pm6yMMdklhgnSxEYL9O4jpzkJagxvReumQGdn2WnHZF6BWTslGcAEKvJPF6_3mVSL4fcK82ilkh-MI5fZTtoIqrcuPDC9SuUldijkn7J_QjNqHJu1gt4jtQ5N2a7KsvXsknLoJ_dPSv-qK4NMmwJLZOWCy2QWcHfqQ0K3lqPB_wh8FhrIZ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3056668572</pqid></control><display><type>article</type><title>Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period</title><source>PubMed Central (Open access)</source><source>Elsevier</source><creator>Quirke, N.P. ; Cullinane, C. ; Turk, M.A. ; Shafique, N. ; Evoy, D. ; Geraghty, J. ; McCartan, D. ; Quinn, C. ; Walshe, J.M. ; McDermott, E. ; Rutherford, C. ; Prichard, R.S.</creator><creatorcontrib>Quirke, N.P. ; Cullinane, C. ; Turk, M.A. ; Shafique, N. ; Evoy, D. ; Geraghty, J. ; McCartan, D. ; Quinn, C. ; Walshe, J.M. ; McDermott, E. ; Rutherford, C. ; Prichard, R.S.</creatorcontrib><description>Invasive lobular carcinoma (ILC) accounts for 5–15% of invasive breast cancers. Typical ILC is oestrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative. Atypical biomarker profiles (ER- and HER2+, ER+ and HER2+ or triple negative) appear to differ from typical ILCs. This study compared subtypes of ILC in terms of clinical and pathological parameters, and response to neoadjuvant chemotherapy (NACT) according to biomarker profile. All patients with ILC treated in a single centre from January 2005 to December 2020 were identified from a prospectively maintained database. Clinicopathologic and outcome data was collected and analysed according to tumour biomarker profile. A total of 582 patients with ILC were treated. Typical ILC was observed in 89.2% (n = 519) and atypical in 10.8% (n = 63). Atypical ILCs were of a higher grade (35% grade 3 vs 9.6% grade 3, p &lt; 0.001). A larger proportion of atypical ILC received NACT (31.7% vs 6.9% p &lt; 0.001). Atypical ILCs showed a greater response to NACT (mean RCB (Residual Cancer Burden Score) 2.46 vs mean RCB 3.41, p = 0.0365), and higher pathological complete response rates (15% vs 0% p = 0.017). Despite this, overall 5-year disease-free survival (DFS) was higher in patients with typical ILC (91% vs 83%, p = 0.001). Atypical ILCs have distinct characteristics. They are more frequently of a higher grade and demonstrate a superior response to NACT. Despite the latter, atypical ILCs have a worse 5-year DFS which should be taken into consideration in terms of prognostication and may assist patient selection for NACT. •ILC is a unique clinical entity and should be considered separately to IBS-NST for research and treatment purposes.•Biomarker profile influences ILC disease behaviour and may have an effect on response to neoadjuvant chemotherapy.•Tumour size and lymph node status are independent predictors of recurrence free survival in ILC.</description><identifier>ISSN: 0960-9776</identifier><identifier>ISSN: 1532-3080</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/j.breast.2024.103739</identifier><identifier>PMID: 38754140</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Breast ; Cancer ; Lobular ; Neoadjuvant chemotherapy</subject><ispartof>Breast (Edinburgh), 2024-08, Vol.76, p.103739, Article 103739</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024. Published by Elsevier Ltd.</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-712c0ee785b8b24806a4d651b5e493e9685c7742a61eb1b7482b25f61dfd645a3</citedby><cites>FETCH-LOGICAL-c474t-712c0ee785b8b24806a4d651b5e493e9685c7742a61eb1b7482b25f61dfd645a3</cites><orcidid>0000-0001-8131-8472</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38754140$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quirke, N.P.</creatorcontrib><creatorcontrib>Cullinane, C.</creatorcontrib><creatorcontrib>Turk, M.A.</creatorcontrib><creatorcontrib>Shafique, N.</creatorcontrib><creatorcontrib>Evoy, D.</creatorcontrib><creatorcontrib>Geraghty, J.</creatorcontrib><creatorcontrib>McCartan, D.</creatorcontrib><creatorcontrib>Quinn, C.</creatorcontrib><creatorcontrib>Walshe, J.M.</creatorcontrib><creatorcontrib>McDermott, E.</creatorcontrib><creatorcontrib>Rutherford, C.</creatorcontrib><creatorcontrib>Prichard, R.S.</creatorcontrib><title>Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>Invasive lobular carcinoma (ILC) accounts for 5–15% of invasive breast cancers. Typical ILC is oestrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative. Atypical biomarker profiles (ER- and HER2+, ER+ and HER2+ or triple negative) appear to differ from typical ILCs. This study compared subtypes of ILC in terms of clinical and pathological parameters, and response to neoadjuvant chemotherapy (NACT) according to biomarker profile. All patients with ILC treated in a single centre from January 2005 to December 2020 were identified from a prospectively maintained database. Clinicopathologic and outcome data was collected and analysed according to tumour biomarker profile. A total of 582 patients with ILC were treated. Typical ILC was observed in 89.2% (n = 519) and atypical in 10.8% (n = 63). Atypical ILCs were of a higher grade (35% grade 3 vs 9.6% grade 3, p &lt; 0.001). A larger proportion of atypical ILC received NACT (31.7% vs 6.9% p &lt; 0.001). Atypical ILCs showed a greater response to NACT (mean RCB (Residual Cancer Burden Score) 2.46 vs mean RCB 3.41, p = 0.0365), and higher pathological complete response rates (15% vs 0% p = 0.017). Despite this, overall 5-year disease-free survival (DFS) was higher in patients with typical ILC (91% vs 83%, p = 0.001). Atypical ILCs have distinct characteristics. They are more frequently of a higher grade and demonstrate a superior response to NACT. Despite the latter, atypical ILCs have a worse 5-year DFS which should be taken into consideration in terms of prognostication and may assist patient selection for NACT. •ILC is a unique clinical entity and should be considered separately to IBS-NST for research and treatment purposes.•Biomarker profile influences ILC disease behaviour and may have an effect on response to neoadjuvant chemotherapy.•Tumour size and lymph node status are independent predictors of recurrence free survival in ILC.</description><subject>Breast</subject><subject>Cancer</subject><subject>Lobular</subject><subject>Neoadjuvant chemotherapy</subject><issn>0960-9776</issn><issn>1532-3080</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp9kc2L1TAUxYsoznP0PxDJ0k2f-U6LIMjgx4MBN7oOt8ntvJS2qUnfg7edv9yMHWfpKnA59_xyz6mqt4zuGWX6w7DvEkJe95xyWUbCiPZZtWNK8FrQhj6vdrTVtG6N0VfVq5wHSmkrdPOyuhKNUZJJuqvuD_MZcjgjGWN3GiERB8mFOU5AYk_WI5IN85G4MczBxQXWYxzjXXBkSbEPIxKYPUmYlzhnJGskM0bww-kM80rcEadYbBIsFxLPmAgQpuoLFtSCKUT_unrRw5jxzeN7Xf36-uXnzff69se3w83n29pJI9faMO4oomlU13RcNlSD9FqxTqFsBba6Uc4YyUEz7FhnZMM7rnrNfO-1VCCuq8Pm6yMMdklhgnSxEYL9O4jpzkJagxvReumQGdn2WnHZF6BWTslGcAEKvJPF6_3mVSL4fcK82ilkh-MI5fZTtoIqrcuPDC9SuUldijkn7J_QjNqHJu1gt4jtQ5N2a7KsvXsknLoJ_dPSv-qK4NMmwJLZOWCy2QWcHfqQ0K3lqPB_wh8FhrIZ</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Quirke, N.P.</creator><creator>Cullinane, C.</creator><creator>Turk, M.A.</creator><creator>Shafique, N.</creator><creator>Evoy, D.</creator><creator>Geraghty, J.</creator><creator>McCartan, D.</creator><creator>Quinn, C.</creator><creator>Walshe, J.M.</creator><creator>McDermott, E.</creator><creator>Rutherford, C.</creator><creator>Prichard, R.S.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8131-8472</orcidid></search><sort><creationdate>20240801</creationdate><title>Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period</title><author>Quirke, N.P. ; Cullinane, C. ; Turk, M.A. ; Shafique, N. ; Evoy, D. ; Geraghty, J. ; McCartan, D. ; Quinn, C. ; Walshe, J.M. ; McDermott, E. ; Rutherford, C. ; Prichard, R.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-712c0ee785b8b24806a4d651b5e493e9685c7742a61eb1b7482b25f61dfd645a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Breast</topic><topic>Cancer</topic><topic>Lobular</topic><topic>Neoadjuvant chemotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quirke, N.P.</creatorcontrib><creatorcontrib>Cullinane, C.</creatorcontrib><creatorcontrib>Turk, M.A.</creatorcontrib><creatorcontrib>Shafique, N.</creatorcontrib><creatorcontrib>Evoy, D.</creatorcontrib><creatorcontrib>Geraghty, J.</creatorcontrib><creatorcontrib>McCartan, D.</creatorcontrib><creatorcontrib>Quinn, C.</creatorcontrib><creatorcontrib>Walshe, J.M.</creatorcontrib><creatorcontrib>McDermott, E.</creatorcontrib><creatorcontrib>Rutherford, C.</creatorcontrib><creatorcontrib>Prichard, R.S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quirke, N.P.</au><au>Cullinane, C.</au><au>Turk, M.A.</au><au>Shafique, N.</au><au>Evoy, D.</au><au>Geraghty, J.</au><au>McCartan, D.</au><au>Quinn, C.</au><au>Walshe, J.M.</au><au>McDermott, E.</au><au>Rutherford, C.</au><au>Prichard, R.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>76</volume><spage>103739</spage><pages>103739-</pages><artnum>103739</artnum><issn>0960-9776</issn><issn>1532-3080</issn><eissn>1532-3080</eissn><abstract>Invasive lobular carcinoma (ILC) accounts for 5–15% of invasive breast cancers. Typical ILC is oestrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative. Atypical biomarker profiles (ER- and HER2+, ER+ and HER2+ or triple negative) appear to differ from typical ILCs. This study compared subtypes of ILC in terms of clinical and pathological parameters, and response to neoadjuvant chemotherapy (NACT) according to biomarker profile. All patients with ILC treated in a single centre from January 2005 to December 2020 were identified from a prospectively maintained database. Clinicopathologic and outcome data was collected and analysed according to tumour biomarker profile. A total of 582 patients with ILC were treated. Typical ILC was observed in 89.2% (n = 519) and atypical in 10.8% (n = 63). Atypical ILCs were of a higher grade (35% grade 3 vs 9.6% grade 3, p &lt; 0.001). A larger proportion of atypical ILC received NACT (31.7% vs 6.9% p &lt; 0.001). Atypical ILCs showed a greater response to NACT (mean RCB (Residual Cancer Burden Score) 2.46 vs mean RCB 3.41, p = 0.0365), and higher pathological complete response rates (15% vs 0% p = 0.017). Despite this, overall 5-year disease-free survival (DFS) was higher in patients with typical ILC (91% vs 83%, p = 0.001). Atypical ILCs have distinct characteristics. They are more frequently of a higher grade and demonstrate a superior response to NACT. Despite the latter, atypical ILCs have a worse 5-year DFS which should be taken into consideration in terms of prognostication and may assist patient selection for NACT. •ILC is a unique clinical entity and should be considered separately to IBS-NST for research and treatment purposes.•Biomarker profile influences ILC disease behaviour and may have an effect on response to neoadjuvant chemotherapy.•Tumour size and lymph node status are independent predictors of recurrence free survival in ILC.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>38754140</pmid><doi>10.1016/j.breast.2024.103739</doi><orcidid>https://orcid.org/0000-0001-8131-8472</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0960-9776
ispartof Breast (Edinburgh), 2024-08, Vol.76, p.103739, Article 103739
issn 0960-9776
1532-3080
1532-3080
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d4ce1749f6524f5b865c548323a5adc4
source PubMed Central (Open access); Elsevier
subjects Breast
Cancer
Lobular
Neoadjuvant chemotherapy
title Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A45%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Invasive%20lobular%20carcinoma%20of%20the%20breast;%20clinicopathologic%20profile%20and%20response%20to%20neoadjuvant%20chemotherapy%20over%20a%2015-year%20period&rft.jtitle=Breast%20(Edinburgh)&rft.au=Quirke,%20N.P.&rft.date=2024-08-01&rft.volume=76&rft.spage=103739&rft.pages=103739-&rft.artnum=103739&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/j.breast.2024.103739&rft_dat=%3Cproquest_doaj_%3E3056668572%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-712c0ee785b8b24806a4d651b5e493e9685c7742a61eb1b7482b25f61dfd645a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3056668572&rft_id=info:pmid/38754140&rfr_iscdi=true